Bone Marrow Transplantation
Conditions
Keywords
Stem cell transplant, fecal microbiota transplantation
Brief summary
This research study is studying an intervention called fecal microbiota transplantation (FMT). Patients who are scheduled to undergo Hematopoietic Stem Cell Transplantation are invited to take part in this clinical trial to undergo empiric FMT soon after hematopoietic engraftment. The primary endpoint will be to assess the feasibility of FMT in this population and to assess safety.
Detailed description
The microbiome (spectrum of bacteria in a patient's gut) is thought to play a role in helping to shape one's immune system given its direct contact with normal cells in our intestine. Recent studies have suggested that a microbiome with very few bacteria (low diversity) seems to be bad for health and a high-diversity microbiome (many different species) appears to be good. This appears to be true even for patients after HSCT where low diversity microbiome status has correlated with infections, GVHD and overall survival. Fecal microbiota transplantation (FMT) is routinely performed for an infection caused by Clostridium difficile but is not yet approved by the FDA as a treatment for any disease. FMT restores a high diversity microbiome. It is hoped that through FMT, overall outcomes after HSCT can potentially be improved. FMT will be performed in the first 3 weeks after recovery of white blood cells after HSCT. The source of FMT will be from healthy 3rd party donors. FMT will be performed through the ingestion of 30 capsules over 2 consecutive days.
Interventions
BIOLOGICALFecal Microbiota Transplantation (FMT)
FMT will be given through the ingestion of 30 capsules (15 capsules daily x 2 consecutive days)
Sponsors
Massachusetts General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Men or women ≥ 18 and ≤ 65 years old * Patients designated to undergo myeloablative or intermediate intensity allogeneic peripheral blood or bone marrow hematopoietic cell transplantation. Consent will be obtained prior to admission for HSCT. Patients receiving any donor source of stem cells are eligible. Eligible conditioning regimens are those defined as myeloablative by Consensus Criteria (Bacigalupo 2009) as well as the combination of fludarabine with melphalan (100-140 mg/mg2) * Any Graft-vs-Host disease (GVHD) prophylaxis regimen is allowed. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%, see Appendix A) * Patients with adequate physical function as measured by * Cardiac: Left ventricular ejection fraction at rest must be ≥ 40%, or shortening fraction \>25%. * Hepatic: * Bilirubin ≤ 2.5 mg/dL, except for patients with Gilbert's syndrome or hemolysis * Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and Alkaline Phosphatase \< 5 x Upper Limit of Institutional Normal Range (ULN). * Renal: Serum creatinine within normal range, or if serum creatinine is outside normal range, then renal function (measured or estimated creatinine clearance or GFR) ≥ 40millileters/min/1.73m2. * Pulmonary: Diffusing lung capacity for carbon monoxide (DLCO) (corrected for hemoglobin), Forced expiratory volume in 1 second (FEV1) and Forced vital capacity (FVC) ≥ 50% predicted. * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for 3 months after FMT. * Ability to understand and the willingness to sign a written informed consent document, including the willingness to accept risk of unrelated donor stool. * Ability to swallow oral medications.
Exclusion criteria
* Prior allogeneic hematopoietic stem cell transplantation. (Patients may have received a prior autologous hematopoietic stem cell transplant.) * Participants who are receiving any other investigational agents. * Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Patients with active or uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy. * Patients with history of primary idiopathic myelofibrosis or any severe marrow fibrosis. * Planned use of prophylactic donor lymphocyte infusion (DLI) therapy. * Delayed gastric emptying syndrome * Known chronic aspiration * Patients with a history of significant allergy to foods not excluded from the donor diet (excluded foods are tree nuts, peanuts, shellfish, eggs) * Pregnant and breast-feeding women are ineligible because they are not eligible for hematopoietic stem cell transplantation. * HIV-positive participants are ineligible. * Participants who are unable to swallow pills. * Participants with end-stage liver disease (cirrhosis) * Participants with acute, active gastrointestinal infection (e.g., typhlitis, diverticulitis, appendicitis) * Participants with inflammatory bowel disease (e.g., ulcerative colitis, Crohn's)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility measured by number of participants able to ingest 15 FMT capsules over a 2-day period | 2 days | Number of participants able to ingest 15 FMT capsules over a 2 day period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | 2 years | — |
| Overall Survival | 2 years | — |
| Cumulative Incidence Of aGVHD | 2 years | — |
| Non-Relapse Mortality Rate | 2 years | — |
| Number of participants with treatment-related adverse events | 1 year | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
Countries
United States
Outcome results
None listed